Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71277 | 0.90 | NR1H2 (0.51) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL28959326 | 0.89 | NR1H2 (0.50) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL14714638 | 0.89 | NR1H2 (0.49) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL20129254 | 0.88 | NR1H2 (0.47) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL30763617 | 0.88 | NR1H2 (0.50) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL16415212 | 0.88 | PRMT5 (0.47) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL16520107 | 0.88 | PRMT5 (0.47) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL15600251 | 0.88 | PRMT5 (0.47) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL16419552 | 0.87 | NR1H2 (0.50) | NR1H2PRMT5WDR77USP2SMN1; SMN2 | |
| SCHEMBL24458928 | 0.85 | NR1H2 (0.49) | NR1H2PRMT5WDR77USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | NR1H2 1171/4885PRMT5 1023/4885WDR77 2784/4885 |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | NR1H2 4052/4885PRMT5 664/4885WDR77 1222/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | NR1H2 778/4885PRMT5 3488/4885WDR77 3634/4885 |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | NR1H2 2948/4885PRMT5 458/4885WDR77 1543/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | NR1H2 4052/4885PRMT5 664/4885WDR77 1222/4885 |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | NR1H2 711/4885PRMT5 112/4885WDR77 851/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | NR1H2 1014/4885PRMT5 1384/4885WDR77 2322/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | NR1H2 3893/4885PRMT5 2061/4885WDR77 870/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | NR1H2 3501/4885PRMT5 511/4885WDR77 916/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | NR1H2 3893/4885PRMT5 2061/4885WDR77 870/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | NR1H2 2582/4885PRMT5 871/4885WDR77 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.